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Albuminemia <30 g/l (p = 0.031) resulted to be a risk factor for 
postoperative complications. HEQ had a better result for RALS 
(p = 0.019), while no differences resulted for SF36, BIQ and GIQLI.
Conclusions: Minimally invasive technique for CD is feasible, even 
for complicated and recurrent disease. Our study demonstrated low 
rates of short- and long-term postoperative complications. No differ-
ence between techniques were demonstrated. Further studies, with a 
larger and sample size and randomised controlled design, should be 
performed to assess the best surgical technique.
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Background: Although the cause of IBD remains largely unknown, 
available evidence suggests that the innate response is greatly 
involved in inducing gut inflammation. Aberrant expression of pat-
tern recognition receptors (PRRs), including the IFI16 protein, in 
colonic biopsies from active ulcerative colitis (UC) and Crohn's 
disease (CD) patients has been independently described (Vanhove 
et  al., Inflamm Bowel Dis 2015; Caneparo et  al., Inflamm Bowel 
Dis 2016). Consistent with the fact that the IFI16 protein is a tar-
get for autoantibodies, we have also demonstrated that its de novo 
overexpression in the gut epithelial cells leads to the development of 
specific autoantibodies in IBD (Caneparo et al., Inflamm Bowel Dis 
2016). To substantiate the clinical utility of these autoantibodies, the 
anti-IFI16 seroresponse was evaluated in a new and larger cohort of 
IBD patients undergoing anti-TNF therapy.
Methods: Sera from 145 IBD patients (31 CD and 114 UC), pro-
spectively harvested before and after infliximab (IFX) therapy, were 
assessed by ELISA for the presence of anti-IFI16 autoantibodies, 
alongside with 182 sera from healthy controls (HC). The patient’s 
antibody statuses were qualitatively and quantitatively associated 
with disease phenotype and response to IFX therapy, endoscopically 
assessed after a median of 12 weeks after first IFX administration. 
Response was defined as the absence of ulcerations or clear endo-
scopic improvement compared with baseline endoscopy in CD, and 
a Mayo endoscopic subscore of 0 or 1 in UC.
Results: Higher prevalence of anti-IFI16 IgG, that tended to 
increase after therapy, was observed in both CD and UC patients 
when compared with HC (p < 0.001). With cut-off levels corre-
sponding to the 95th percentile of the distribution in the control 
population (113 U/ml), 61% of CD patients before and 74% after 
therapy, and 55% of UC patients before and 61% after therapy 
tested positive for anti-IFI16 IgG antibodies (p  =  0.21 for CD, 
p = 0.92 for UC, McNemar test) in comparison with 6% of HC. 
Univariate analysis showed that low levels of autoantibodies at 
baseline significantly correlated with response to IFX therapy in 
CD (p = 0.004, Mann–Whitney U test).
Conclusions: In this validation cohort of IBD patients undergoing 
anti-TNF therapy, we replicated that anti-IFI16 IgG prevalence is 
significantly higher in both CD and UC patients, compared with 
HC. Additionally, we established that low levels of anti-IFI16 IgG 
at baseline significantly correlate with endoscopic response to IFX. 
Even if larger prospective data are needed to justify the use of anti-
IFI16 antibodies as predictive biomarker for IFX therapy, altogether 
these results substantiate the need to focus on the biological and clin-
ical significance of the IFI16 protein and specific antibodies in IBD.
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Abstract P601 – Figure. Proportion of subjects who discontinued corticosteroid and achieved clinical and endoscopic endpoints at 16 weeks.
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